{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-25-000044","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.170740+00:00","generated_at":"2026-05-22T01:09:52.996774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ANI Pharma posts record Q1 revenue $197.1M (+43%); raises FY2025 guidance","bullets":["Record Q1 net revenue $197.1M (+43.4% YoY); Rare Disease $69.0M (Cortrophin Gel $52.9M, +43.1%).","Record adjusted non-GAAP EBITDA $50.7M (+34.9%); adjusted diluted EPS $1.70, up from $1.21 YoY.","Generics revenue $98.7M (+40.5%) driven by new launches including first-to-market prucalopride.","Raised 2025 guidance: net revenue $768M-$793M, EBITDA $195M-$205M, adjusted EPS $6.27-$6.62."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-25-000044","json":"https://secwatch.observer/filing/0001023024-25-000044.json","markdown":"https://secwatch.observer/filing/0001023024-25-000044.md","text":"https://secwatch.observer/filing/0001023024-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/0001023024-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/ani-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:09:52.996774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}